What smart money is saying about Intra-Cellular Therapies, Inc.
ITCI
No fund has written a full thesis on Intra-Cellular Therapies, Inc. in our archive, but 1 fund letter reports a position in it, most recently Timesquare US Small Cap Growth in March 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
1
Sold
1
Letter
Position history
Every position in Intra-Cellular Therapies, Inc. on record in the archive was reported in Q1 2025, across 1 fund letter, with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q1 2025 | 1 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- March 2025
“Intra-Cellular Therapies Inc. is focused on the discovery and development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders. The company agreed to be acquired by Johnson & Johnson, and we sold out of the position which climbed 54% for the time it was held in the quarter.”
Intra-Cellular Therapies, Inc.
Read the letters behind these Intra-Cellular Therapies, Inc. positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger